deucravacitinib + famotidine

A **combination of deucravacitinib and famotidine**. - **Deucravacitinib** is an oral, small molecule inhibitor of *tyrosine kinase 2 (TYK2)* developed and marketed for moderate-to-severe plaque psoriasis. It selectively binds the regulatory domain of TYK2, blocking cytokine signaling for *IL-23, IL-12, and type I interferons*, decreasing inflammation associated with psoriasis[1][4][6]. Developed by Bristol Myers Squibb, it is marketed under the brand name Sotyktu[1][6]. - **Famotidine** is a histamine H2 receptor antagonist that inhibits gastric acid secretion, used mainly in the treatment of gastric ulcers, gastroesophageal reflux disease (GERD), and related conditions. Developed by Merck and available under the brand name Pepcid, it acts as a competitive antagonist at the H2 receptor in parietal cells, reducing gastric acid output. Currently, there is **no approved or uniquely branded combination product** containing both deucravacitinib and famotidine. Both are available as separate oral drugs. No specific clinical indication exists for the combination, but co-administration is pharmacologically possible with no significant pharmacokinetic interaction reported[5].

Other names

deucravacitinibfamotidine